CO2021014370A2 - Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen - Google Patents
Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyenInfo
- Publication number
- CO2021014370A2 CO2021014370A2 CONC2021/0014370A CO2021014370A CO2021014370A2 CO 2021014370 A2 CO2021014370 A2 CO 2021014370A2 CO 2021014370 A CO2021014370 A CO 2021014370A CO 2021014370 A2 CO2021014370 A2 CO 2021014370A2
- Authority
- CO
- Colombia
- Prior art keywords
- present disclosure
- dosage regimens
- disclosure describes
- compositions
- rsv antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840701P | 2019-04-30 | 2019-04-30 | |
| PCT/US2020/030619 WO2020223435A1 (en) | 2019-04-30 | 2020-04-30 | Dosage regimens for and compositions including anti-rsv antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021014370A2 true CO2021014370A2 (es) | 2021-10-29 |
Family
ID=70779897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0014370A CO2021014370A2 (es) | 2019-04-30 | 2021-10-26 | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US12024553B2 (https=) |
| EP (1) | EP3962940A1 (https=) |
| JP (2) | JP2022531205A (https=) |
| KR (1) | KR20220002427A (https=) |
| CN (1) | CN113825767A (https=) |
| AU (1) | AU2020265676A1 (https=) |
| BR (1) | BR112021020846A2 (https=) |
| CA (1) | CA3138180A1 (https=) |
| CO (1) | CO2021014370A2 (https=) |
| EA (1) | EA202192776A1 (https=) |
| IL (1) | IL287443A (https=) |
| MX (1) | MX2021013248A (https=) |
| SG (1) | SG11202111748TA (https=) |
| TW (1) | TWI861099B (https=) |
| WO (1) | WO2020223435A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
| WO2023039584A2 (en) * | 2021-09-13 | 2023-03-16 | Medimmune Limited | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
| PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
| LT2950886T (lt) | 2013-02-01 | 2020-07-10 | Medimmune, Llc | Respiracinio sincitinio viruso f baltymo epitopai |
| FR3008921B1 (fr) | 2013-07-23 | 2015-12-25 | Safran | Piece en materiau composite avec portion de conductivite thermique et electrique et procede de fabrication d'une telle piece |
| EP4353316A3 (en) | 2014-01-15 | 2024-08-21 | Medimmune Limited | Rsv-specific antibodies and functional parts thereof |
| BR112019018022A2 (pt) | 2017-03-01 | 2020-06-02 | Medimmune Limited | Formulações de anticorpos monoclonais |
| TWI761453B (zh) | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
-
2020
- 2020-04-27 US US16/859,750 patent/US12024553B2/en active Active
- 2020-04-30 AU AU2020265676A patent/AU2020265676A1/en active Pending
- 2020-04-30 MX MX2021013248A patent/MX2021013248A/es unknown
- 2020-04-30 US US17/606,614 patent/US20220204593A1/en active Pending
- 2020-04-30 TW TW109114519A patent/TWI861099B/zh active
- 2020-04-30 CA CA3138180A patent/CA3138180A1/en active Pending
- 2020-04-30 EA EA202192776A patent/EA202192776A1/ru unknown
- 2020-04-30 CN CN202080032470.XA patent/CN113825767A/zh active Pending
- 2020-04-30 WO PCT/US2020/030619 patent/WO2020223435A1/en not_active Ceased
- 2020-04-30 BR BR112021020846A patent/BR112021020846A2/pt unknown
- 2020-04-30 KR KR1020217038129A patent/KR20220002427A/ko active Pending
- 2020-04-30 JP JP2021564373A patent/JP2022531205A/ja active Pending
- 2020-04-30 SG SG11202111748TA patent/SG11202111748TA/en unknown
- 2020-04-30 EP EP20727466.3A patent/EP3962940A1/en active Pending
-
2021
- 2021-10-20 IL IL287443A patent/IL287443A/en unknown
- 2021-10-26 CO CONC2021/0014370A patent/CO2021014370A2/es unknown
-
2024
- 2024-05-20 US US18/669,241 patent/US20240417447A1/en active Pending
-
2025
- 2025-01-31 JP JP2025014950A patent/JP2025072444A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA202192776A1 (ru) | 2022-01-19 |
| JP2025072444A (ja) | 2025-05-09 |
| TWI861099B (zh) | 2024-11-11 |
| US20220204593A1 (en) | 2022-06-30 |
| JP2022531205A (ja) | 2022-07-06 |
| CN113825767A (zh) | 2021-12-21 |
| WO2020223435A1 (en) | 2020-11-05 |
| TW202106333A (zh) | 2021-02-16 |
| CA3138180A1 (en) | 2020-11-05 |
| AU2020265676A1 (en) | 2021-11-18 |
| SG11202111748TA (en) | 2021-11-29 |
| BR112021020846A2 (pt) | 2022-01-18 |
| US20240417447A1 (en) | 2024-12-19 |
| US20200347120A1 (en) | 2020-11-05 |
| EP3962940A1 (en) | 2022-03-09 |
| KR20220002427A (ko) | 2022-01-06 |
| MX2021013248A (es) | 2022-01-24 |
| IL287443A (en) | 2021-12-01 |
| US12024553B2 (en) | 2024-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| CR20190162A (es) | Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado | |
| MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
| MX2017006312A (es) | Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20. | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| CO2022002573A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| CR20190468A (es) | Métodos para tratar enfermedades y trastornos mediados por completo | |
| MX2017000627A (es) | Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| BR112021015036A2 (pt) | Tratamento para câncer com imunoconjugados do anticorpo ror1 | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| JOP20220104A1 (ar) | نظام تجريع لعوامل مضادة لـ dll3 | |
| GEAP202516662A (en) | Anti-nectin-4 antibody, conjugate including same, and application thereof | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| MX2022002636A (es) | Tratamiento de la enfermedad o trastorno hepatico que comprende los antagonistas del receptor de actrii. | |
| CO2021014370A2 (es) | Regímenes de dosificación para anticuerpos anti-vrs y composiciones que los incluyen | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| MX2022001065A (es) | Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo. | |
| CL2019003533A1 (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| AR119159A1 (es) | Tratamientos de angioedema | |
| BR112023026992A2 (pt) | Medicamento para o tratamento e/ou prevenção do câncer, agentes que aumentam a eficácia do medicamento em uma composição farmacêutica e método para tratar e/ou prevenir o câncer | |
| ECSP23076276A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1 | |
| CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
| MX2020004074A (es) | Producto de combinacion para el tratamiento de cancer. |